Danaher Corporation
216.90-4.11 (-1.86%)
Oct 28, 4:00:02 PM EDT · NYSE · DHR · USD
Key Stats
Market Cap
153.21BP/E (TTM)
44.63Basic EPS (TTM)
4.86Dividend Yield
0.01%Recent Filings
8-K
10-Q
8-K
Danaher updates by-laws, authorizes buybacks
Danaher Corporation amended its by-laws on September 9, 2025, tightening shareholder advance notice rules for proposing business and nominating directors, alongside routine updates. The board also greenlit a new repurchase program for up to 35 million common shares, flexible in execution with no expiration. This bolsters capital returns amid market discretion. Yet, repurchases hinge on business conditions.
8-K
GC Ellis to step down
Danaher Corporation's Senior Vice President and General Counsel Brian W. Ellis plans to step down from his legal role on August 25, 2025, but will remain as Senior Vice President until retiring fully on February 28, 2026. This transition ensures continuity in executive leadership during the handover. No successor named yet.
8-K
Danaher CFO transition announced
Danaher Corporation announced on July 21, 2025, that CFO Matthew McGrew will step down effective February 28, 2026, transitioning to a continued Executive Vice President role amid his retirement plans after over 20 years. Matthew Gugino, 43, with deep internal finance experience including Investor Relations and Life Sciences oversight, will succeed him. This handover ensures continuity in financial strategy amid growth pursuits. Seamless transitions build legacies.
IPO
Website
Employees
Sector
Industry
A
Agilent Technologies, Inc.
145.85-0.74
APDN
Applied DNA Sciences, Inc.
5.62+1.35
BIO
Bio-Rad Laboratories, Inc.
330.42-5.70
BRKR
Bruker Corporation
38.72+0.08
DGX
Quest Diagnostics Incorporated
178.28-1.98
ILMN
Illumina, Inc.
97.80-2.55
QGEN
Qiagen N.V.
47.95-0.45
TECH
Bio-Techne Corp
63.94-0.31
TMO
Thermo Fisher Scientific Inc
557.63-6.15
WAT
Waters Corporation
345.95-5.80